N
ANAB icon

Natixis’s AnaptysBio ANAB Stock Holding History

Natixis’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-333
Closed -$18.5K – 1162
2026
Q1 		$18.5K Buy
+333
New +$17.9K ﹤0.01% 1009
2025
Q2 		– Sell
-2,669
Closed -$48.8K – 1030
2025
Q1 		$48.8K Buy
+2,669
New +$44.5K ﹤0.01% 834
2022
Q2 		– Sell
-16,300
Closed -$403K – 1149
2022
Q1 		$403K Sell
16,300
-142,700
-90% -$4.32M ﹤0.01% 1017
2021
Q4 		$5.53M Buy
+159,000
New +$5.04M 0.02% 535

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Natixis's ANAB Position: Q2 2026 in Review

Natixis sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 333 shares — an estimated $18.5K sold.

Natixis first reported a position in ANAB in Q4 2021 and held it in 4 quarters. The position peaked at $5.53M in Q4 2021. 214 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Natixis reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 333 AnaptysBio shares in Q2 2026, an estimated $18.5K.
  • Natixis first reported a position in AnaptysBio in Q4 2021 and held it in 4 quarters.
  • Natixis's AnaptysBio position peaked at $5.53M in Q4 2021.
  • 214 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.